Clinical Trial Update: Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of maribavir versus investigator-assigned treatment for CMV infections refractory or resistant to standard antiviral…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection in Transplant Recipients

Drugs mentioned

• Maribavir (maribavir)

Snippet

Sponsor: Shire | Conditions: Cytomegalovirus (CMV) | Phase 3 | Status: COMPLETED | Results posted: 2021-09-23